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ABSTRACT 
Title:  Prevalence of gynaecological disease in women with an hMLH1 mutation in the 
Northern Cape Province – Survey of a population with Lynch syndrome in South Africa 
Objective:  Lynch syndrome, previously called hereditary non-polyposis colorectal cancer 
(HNPCC), is one of the most common hereditary cancer syndromes with an association with 
gynaecological cancers.  Members of affected families have an increased risk for colon 
cancer as well as extra colonic sites; in particular endometrial and ovarian cancer.   
A cohort of patients with Lynch syndrome in the Northern Cape, South Africa has been 
identified and followed up.  
According to recommendations by the International Collaborative Group on HNPCC (ICG-
HNPCC); women affected with the gene mutation warrant full gynaecological assessment to 
exclude endometrial and ovarian cancer. Thus far the recommended screening has not been 
possible and the apparent prevalence of gynaecological cancer or premalignancies among this 
high risk group has not been established. The aim of this study was to determine the actual 
apparent prevalence of gynaecological pathology in this cohort of patients; by way of 
screening. 
Methods:  Women with a known gene mutation, or close relatives of affected family 
members, utilising the annual colorectal service in the Northern Cape, who fulfilled the 
inclusion criteria, were recruited to undergo gynaecological evaluation.  The participants had 
a gynaecological examination which included a Papanicolaou smear, a pelvic ultrasound and 
endometrial sampling.  The resultant data was captured on an Excel spread sheet and a 
descriptive analysis was done. 
Results:  In total 43 women were recruited, of which 18 were postmenopausal and 25 
premenopausal. 35 of these women had a known hMLH1 gene mutation.  The eight 
remaining women had either normal genotyping (n=7) or were awaiting molecular test results 
(n=1). 
Only twenty-one of these participants agreed to endometrial sampling, in addition to pelvic 
ultrasound and gynaecological examination. Histological results were therefore available for 
the 21 participants. One patient was diagnosed with a grade-2 endometroid adenocarcinoma. 
No cases of endometrial hyperplasia were found.   
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Thirty pelvic ultrasound scans were performed.  Of these, one patient had an enlarged 
adnexal mass. No cervical premalignancies were diagnosed on cervical smears, with one 
abnormal smear of atypical cells of unknown significance (ASCUS) diagnosed. 
Conclusion:  The apparent prevalence of gynaecological disease in this study population was 
lower than expected. We conclude however that this high risk group of women should still 
undergo regular gynaecological screening which should include history taking and clinical 
examination.  Screening using routine endometrial sampling and pelvic ultrasound in 
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CHAPTER 1:  INTRODUCTION AND LITERATURE REVIEW 
Background 
Epidemiological studies have long recognised the association between a positive family 
history of a cancer and a susceptibility of other family members to the same cancer type. 
Approximately 10% of cancers arise as a result of a genetic predisposition, but less than 5% 
will arise as a result of a single highly penetrant cancer predisposition gene. These single 
gene disorders which are inherited are also termed cancer susceptibility syndromes, in which 
family members who carry the gene mutation are at high risk of developing various cancers.  
These family members tend to develop these cancers at a young age, compared to the general 
population [1]. 
The two most common hereditary syndromes associated with gynaecological cancer are 
hereditary breast and ovarian cancer syndrome (mutation in genes BRCA 1 and BRCA 2) and 
Lynch syndrome.  Lynch syndrome, previously called Hereditary Non Polyposis Colorectal 
Cancer (HNPCC) is thought to be caused by a mutation in mismatch repair (MMR) genes. 
The four most common mutated gene subtypes in Lynch syndrome tumours are hMLH1, 
hMSH2, MSH6 and PMS2 [2]. 
Lynch syndrome 
Lynch syndrome is one of the earliest recognised and most prevalent familial cancer 
syndromes which was formally described by Henry Lynch in 1966 [3].  The syndrome is 
defined as an inherited condition (autosomal dominant) involving defective DNA mismatch 
repair (MMR) system. The MMR genes repair base pair errors during cell division.  A 
mutation in any of the MMR genes results in loss of function of the encoded protein.  This 
change in the gene product leads to microsatellite instability (MSI) which refers to a 
molecular phenotype with alterations in repetitive DNA sequences.  Lynch associated 
tumours can be assayed through immunohistochemistry to prove MSI.  There are five known 
MutS genes (MSH2, MSH3, MSH4, MSH5 and MSH6) and four MutL genes (MLH1, 
PMS1, PMS2 and MLH3) in the human MMR system.   
The syndrome has a worldwide population prevalence of approximately 1 in 600 to 1 in 3000 
[4].   These affected families have an increased risk of colon as well as extra colonic cancers; 
in particular, endometrial cancer.  Other extracolonic sites associated with the genetic defect 
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include: cancer of the ovary, urinary tract, hepatobiliary tract, brain, small bowel and 
pancreatic cancer.  
Prior to molecular genetic testing, Lynch syndrome was diagnosed by an algorithm using 
clinical and family history criteria.  This criterion is known as the Amsterdam criteria I and 
was developed by the ICG-HNPPC in 1991.  This was amended to the Amsterdam criteria II 
in 1999 and includes the spectrum of extracolonic cancers (see appendices 6).  There have 
been studies to suggest an increase in breast cancer as another extracolonic cancer [5] but 
currently, breast cancer is not included as part of the diagnostic criteria according to 
Amsterdam II.   
With the discovery of microsatellite instability, diagnosing Lynch syndrome changed 
dramatically. Guidelines were developed to assess which tumours needed to be tested for 
MSI; these are known as the Bethesda guidelines and were revised in 2004.  Once MSI has 
been proven, the patient may be offered further germline DNA testing to confirm the 
presence of Lynch syndrome [6]. 
Risk of endometrial and ovarian cancer  
Endometrial cancer is the second most common malignancy (after colon cancer) seen in 
females with Lynch syndrome, and appears to occur at an earlier age than sporadic cancer.  
The estimated cumulative risk is as high as 40% by the age of 70 years in mutation carriers 
and 15% for first degree relatives (without the genetic abnormality) compared to 3% in the 
general population [7]. Females with the genetic defect also have an up to nine time higher 
risk to develop ovarian cancer (8-12%) [8].  
There have been numerous studies which have emphasized that woman with Lynch syndrome 
have an equal or even greater risk of endometrial cancer than colon cancer [9]. Although we 
do not screen for endometrial and ovarian cancer in the general population, the high 
prevalence of these cancers in female mutation carriers warrants screening. For these reasons 
gynaecological surveillance has been recommended by the International Collaborative Group 
on HNPCC (ICG-HPCC) for asymptomatic cases [10].  
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Endometrial cancer  
Endometrial cancer is the second most common gynaecological cancer in the general world 
population, second only to cervical cancer [11]. It has an even higher incidence in more 
developed countries being the 4th most common cancer.   
According to Globocan 2012, endometrial cancer accounts for 4.8% (319 605) of the total 
new cancer cases and 2.1% (76 160) of the total cancer deaths worldwide [11].  The higher 
incidence in more developed countries can be attributed to the high rates of obesity and also 
to increased detection rates, with patients presenting with early disease. Risk factors for 
developing endometrial cancer are mainly associated with increased hormonal levels and this 
include a high BMI (bone mass index), low parity, early menarche (<13 years old) and late 
menopause (>55).  Protective factors include a later menarche, oral contraceptive use 
(≥1year) and a higher parity (≥1). Most females diagnosed with endometrial cancer are over 
the age of 60.   
Although this cancer has an excellent 5-year survival when detected early (70-90% of FIGO 
stage 1 and 2), one fifth of cases have a poor prognosis [12].   
The proportion of hereditary endometrial cancer due to Lynch syndrome is estimated at 1.8% 
in the general population [13].  The average age for development of endometrial cancer in 
this population is estimated at 50, thus much earlier than in the general population [14].  The 
prognosis when diagnosed in the early stage of disease progression seems to be favourable 
with 5-year survival rate as high as 88% [15].   
The majority of Lynch syndrome associated endometrial cancers are of endometroid 
histology, similar to sporadic endometrial cancer. However, non-endometroid subtypes, 
including uterine serous carcinoma, clear cell carcinoma and uterine malignant mixed 
mullerian tumors, have been reported in women with Lynch syndrome [15]. These 
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Ovarian cancer 
In the general population ovarian cancer is the third most common gynaecologic malignancy 
in the developed world. In 2008, about 225,000 women around the world were diagnosed 
with ovarian cancer.  Mortality was estimated at 140,000 from this disease [16]. 
In the developing world it has an incidence of 5 per 100,000 and a mortality rate of 3.1 per 
100,000.   Screening for ovarian cancer in the general population is not recommended as 
there is insufficient data to suggest benefit for widespread screening. 
The lifetime risk of ovarian cancer in women with Lynch syndrome is estimated to be 8-12% 
compared with 1.5 percent in the general population [9]. These women also tend to develop 
ovarian cancer at a younger age than the general population (43 - 50 versus 60 years old) 
[17]. 
Histopathology and survival outcomes seem to be similar in women with Lynch-associated 
ovarian cancer and women with sporadic ovarian cancer. The most common histologic 
subtype seen in ovarian cancer associated with Lynch syndrome is epithelial serous, but 
endometroid, clear cell and mucinous subtypes, have been reported [18]. 
The higher incidence of ovarian cancer in Lynch syndrome females may justify screening and 
recommendations for this high risk group have been developed by various centres around the 
world [19].    
Recommended gynaecological surveillance in patients with Lynch syndrome 
With the high survival rate associated with endometrial cancer in Lynch syndrome patients, 
the role of gynaecological surveillance in asymptomatic women is unclear. The goal of 
monitoring in these women at high risk of endometrial cancer would be to diagnose cancer at 
an earlier stage and thus minimize the extent of treatment.  Surveillance programs aimed at 
detecting colorectal cancer or precancerous lesions in people with Lynch syndrome have been 
highly successful in decreasing mortality and morbidity [20].  However there is paucity of 
data to suggest a benefit in gynaecological surveillance in asymptomatic women. Various 
prospective and retrospective studies have failed to show the effectiveness of gynaecologic 
surveillance procedures [21; 22].  The lifetime risk of endometrial and ovarian cancer is high 
in women with Lynch syndrome.  Many of these women may not be aware of their risk or be 
able to recognise early symptoms of disease.   
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In the case of endometrial cancer many of affected women are premenopausal and might not 
seek medical attention in the event of irregular periods.  Screening then appears to be justified 
and the ICG-HNPCC suggests annual or biannual screening from the age of 30 year old in 
asymptomatic women. 
Thus far no randomised controlled trials have been done to prove whether gynaecological 
screening would be effective in diagnosing early endometrial or ovarian cancer in Lynch 
syndrome.   
Screening techniques aimed at evaluation of the endometrium, include transvaginal 
ultrasound and endometrial sampling or biopsy.  The value of ultrasonography alone in 
evaluating the endometrium in patients with Lynch syndrome would be limited as 25% of 
endometrial cancers occur in premenopausal women [23].  Biopsy of the endometrium 
improves the sensitivity of the screening technique [24].  The screening recommendation 
states that women with a known genetic mutation or who are at risk based on a genetic 
mutation in her family should be offered annual endometrial biopsy starting at age 30 to 35 
years [19]. 
Transvaginal ultrasound may also assist in evaluating ovarian morphology and is 
recommended annually.  Studies focussing on surveillance for ovarian cancer in high risk 
population groups have unfortunately not been very successful in detecting early ovarian 
cancer.  As this disease usually presents late and has a poor outcome once symptomatic, 
gynaecological screening by way of transvaginal ultrasound in these at risk females is still 
advised.    
Tumour markers may play a role in screening for ovarian cancer in Lynch syndrome patients.   
Measuring the serum concentration of the CA-125 glycoprotein antigen could indicate 
ovarian cancer in about 50 percent of women with early disease and over 80 percent of 
women with advanced ovarian cancer in the general population [25].  However the specificity 
of this screening test is low because serum levels may fluctuate in healthy women according 
to their menstrual cycle.  It can also be raised in a number of other benign or non-benign 
gynaecological and medical diseases making this test not the ideal screening test.   
Combining transvaginal ultrasound and CA125 levels might improve the specificity and 
some centres advise this combination 6 monthly or annually [26].  
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The Northern Cape study population 
In the mid-1980s a family in a rural part of the Northern Cape was identified with most 
members diagnosed with colorectal cancer.  The family was investigated and found to have 
Lynch syndrome with a mutation in the hMLH 1 gene.  This was the first familial case of 
colorectal cancer to be described in South Africa [27].  Subsequently more than 1500 people, 
most of them living in the Northern Cape province of South Africa, have been recognised as 
having a high risk for Lynch syndrome based on their individual family tree [27]. These 
families are mostly of mixed race ancestry and Afrikaans speaking. The Northern Cape is the 
largest province in the country but with the smallest population size of 1,145 861 people [28].  
The majority (75%) of the population lives in small towns, with minimal access to health care 
facilities. 
For the last 20 years these patients diagnosed with Lynch syndrome have and still are 
receiving annual screening for colon cancer by a mobile unit travelling from Groote Schuur 
Hospital in Cape Town to the four temporary screening sites.  
Aim of our study 
Due to poor socio economic circumstances and few resources available to this group of 
patients, the recommended gynaecological screening thus far has not been possible. The 
apparent prevalence of gynaecological cancers or pre-cancerous lesions, particularly of 
endometrial and ovarian origin, among this high risk group has not been established. In 
addition, the risk factors present in this study population associated with gynaecological 
disease will also be defined.   
The main aim of the survey was to determine the prevalence of gynaecological pathology in 
patients with Lynch syndrome included in our study and specifically to screen for 
endometrial and ovarian cancer.  Although cervical cancer is not included in the extracolonic 
tumour spectrum in patients with Lynch syndrome, screening for this cancer in this 
population with limited resources is crucial. Cervical cancer is the second most prevalent 
cancer (after breast) in Southern Africa and other developing countries, and a gynaecological 
risk profile analysis would be incomplete without this type of screening. 
The data obtained by gynaecological screening of these women with the mutation will prove 
valuable to determine future gynaecological screening requirement and management. 
GROOTE SCHUUR OBSTETRICS AND GYNAECOLOGY DEPARTMENT 
 
14 | P a g e  
 
CHAPTER 2:   METHODS 
Study design  
This descriptive / observational study aimed to assess the gynaecological health status of this 
high risk group. 
 
Aim 
To evaluate the prevalence of gynaecological cancerous and pre-cancerous lesions in patients 




1.  To determine the prevalence of endometrial cancer 
2.  To determine the prevalence of ovarian cancer 
3. To screen for cervical abnormalities 
4. To define risk factors associated with gynaecological disease 
 
Ethical considerations 
Participation was entirely voluntary and patients were required to give written informed 
consent prior to the interviews (see Appendix A).  
Ethical approval was acquired from the Research Ethics Committee of the University of Cape 
Town (REC REF 3435/5454, see Appendix B).  Females known with the hMLH1 gene 
mutation were identified from the database within the Division of Human Genetics at UCT.   
 
Setting  
This study was conducted amongst known MLH1 mutation carrier female patients currently 
utilizing colorectal screening at various sites in Northern Cape.  
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This study was planned to coincide with the annual colorectal screening program at the four 
facilities in the Northern Cape, during a week-long screening period beginning September 
2015.  We visited Harrie Surtie hospital (Upington), Springbok hospital, Alexander Bay 
Community Health Centre and Garries hospital.  
No power calculation was done as this study set out to determine gynaecological pathology in 
this patient population.  We aimed to screen as many patients as possible that fitted our 
inclusion criteria.  The sample size was determined by the time frame of the colorectal 
outreach and we anticipate that the results of our study would provide the basis upon which a 




Proven hMLH1 mutation carrier or first degree relative of a carrier 
Client able to give informed consent 
Female patients above 18 
Not pregnant/ pregnancy excluded 
 
Exclusion criteria 
Consent withheld  
Clients not fulfilling inclusion criteria  
 
By interviewing the female clients with Lynch syndrome who fulfilled the inclusion criteria, 
we aimed to gain insight into their reproductive history and current gynaecological profile.  
We assessed for certain risk factors predisposing to gynaecological malignancy, particularly 
endometrial and ovarian cancer. 
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Eligible patients not willing to participate in the study were assured that this would not 
jeopardise their current or future treatment. All patient queries were appropriately managed 
by the primary investigator.  Participants were informed they could withdraw from the study 
at any time. 
Their identity was coded on the data base and therefore not linked to the individual. They 
were guaranteed anonymity. Patients were not offered any remuneration to take part in the 
study. 
 
Data including demographical information as well as a complete obstetrical and 
gynaecological history was collected from all consenting participants. This was followed by a 
clinical examination.   
 
The patients were asked general and specific questions to assess for gynaecological cancer 
risk factors, information on smoking history, HIV status and previous personal and family 
history of gynaecological or other malignancies.  (See Appendix 4) 
The patients were all examined and had ultrasound imaging and endometrial sampling by 
either the primary investigator or supervisor.  A cervical smear was taken to conclude a 
complete gynaecological screening.  Thereafter, the uterus and adnexa were assessed by 
transvaginal ultrasonography (see Appendix 5); prior to endometrial sampling.  Limitations in 
accurate assessment of the uterus and adnexa were documented.   
The ultrasound machine was used with had the following specifications:  
 Mindray® M7 portable unit 
 Midrange TV probe at 4-10 MHz 
 7 MHz centre frequency 
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The following measurements were taken: 
 Length of the uterus in mm (millimetre) 
 Endometrial thickness (ET) in mm 
 Left and right ovary, with the largest diameter measured in mm 
An endometrial biopsy was taken where allowed, to screen for endometrial abnormalities.  
The biopsy was fixed using a standardised technique with 10ml formaldehyde (10%).  The 
specimens collected were safely transported back to the NHLS laboratory at GSH. 
Measurement of serum CA-125 in all participants was considered but due to the low 
specificity of the test and the cost involved, serology was omitted.  
 
Data Management and Statistical analysis 
The data were analysed using descriptive statistics. Numerical data were described using 
appropriate summary statistics, such as the mean, standard deviation, median and range.  
Results were graphically displayed using flow diagrams, bar graphs and proportional data as 
pie charts.  
 
Data Collection and Management 
All data extracted was secured in an excel file and was password protected.  
Each client was allocated a unique study number to protect client confidentiality. 
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CHAPTER 3:  RESULTS 
Recruitment 
Initially 48 women were identified to be screened gynaecologically.  
Five of these women were excluded from our study results as they have been previously 
assessed by the Genetics department of GSH to be of low risk (general population risk) for 
Lynch syndrome. These five women were still screened for gynaecological pathology as they 
were present at the screening facilities and requested to be seen by one of the gynaecologists.  
All of them were of no genetic risk to having Lynch syndrome. Two of the five women had 
surgical indications for annual colonoscopic screening. 
In total, 43 women who met the entrance criteria were included in our study, of which 18 
were postmenopausal and 25 premenopausal.  Of these 43 participants, 35 had a proven 
hMLH1 mutation, 1 was awaiting her test result (blood sample genetic testing) and 7 
participants were first line family members of an affected mutation carrier and tested negative 
for the mutation.   
Thirty of the participants consented to examination and transvaginal ultrasonography. One 
patient was too ill to examine and was sent to the emergency unit of the screening facility.  
She had known chronic airway disease and had an acute episode of lower airway obstruction.   
The remaining twelve participants either refused examination or had a previous 
hysterectomy.  
Twenty-one of the 35 hMLH1 mutation positive participants gave consent to full 
gynaecological screening which included a gynaecological examination (including a 
papsmear), transvaginal ultrasound and endometrial biopsy. Histology results were available 
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Demographic and socio-economic status analysis of the 43 participants 
Age distribution 
The age of the participants ranged from 19 to 70 years .The average age was 44 years.  
 
Figure 2: Age distribution 
 
 
Level of education 
Five (11.6%) women had some level of tertiary education, eight (18.6%), had matric level of 
education, 26 (60.4%) had high school level of education, 3 (6%) had a primary school level 
of education and 1 (2%) woman had received no formal education.  
Employment status 
21 (49 %) women were unemployed and 22 (51%) women had some formal employment. 
Smoking history 
At the time of interview 14(33%) smoked cigarettes while 9 (20%) had stopped smoking 
more than 6 months earlier. 
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Access to health care 
Table 1: Distance travelled to nearest district hospital 
DISTANCE FREQUENCY PERCENTAGE 
0-20 KM 12 28.0 
21-50 KM 7 16.2 
51-100 KM 11 25.6 
101-200 KM 10 23.2 
> 200 KM 3 7.0 
TOTAL 43 100.0 
 
As illustrated in Table 1, more than half of the participants (55.8%) live more than 51 
kilometre (km) from the nearest district hospital where the screening facilities were set up.   
 
Gynaecological and relevant medical history 
Menarche 
The age range of menarche was 11 years to 19 years. Two participants could not remember 
the age of their menarche.  The median age of menarche was 15 years old. 
Parity 
Five participants had never been pregnant and one had no live children with a previous 
miscarriage.  18.6% (n=8) gave birth to 1 child, 34.8% (n= l5) gave birth to 2 children, 18.6% 
(n=8) gave birth to 3 children, 11.6% (n=5) gave birth to 4 children and 0.2% (n=1) gave 
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Table 2  Parity 
No of children ≤ 1 2 3 4 5 
n 14 (6+8) 15 8 5 1 
Percentage 32.6 34.9 18.6 11.7 0.2 
Total (n=43)      
 
Menopausal status 
Of the 43 participants included, 18 were postmenopausal and 25 premenopausal.  Five of the 
18 postmenopausal clients had previous total abdominal hysterectomies. The indications for a 
hysterectomy were: 
 1 previous high grade cervical intra epithelial lesion 
 3 abnormal uterine bleeding 
One premenopausal participant had a previous total hysterectomy.  The indication was for a 
high grade cervical intra epithelial lesion.  
None of these hysterectomies and/or salpingo-oophorectomies was done for endometrial or 
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BMI is usually categorised into four categories, underweight (BMI less than 20 kg/m2), 
normal (BMI between 20-25 kg/m2), overweight (BMI between 25 and 30 kg/m2) and obese 
(BMI over 30kg/m2).  Of the 43 participants included, data for 7 were not available. 
 One (2.7%) was underweight  
 Seven (19.4%) were of normal weight 
 Twelve (33.3%) were overweight 


















Menopausal status with/without previous TAH
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Contraceptive use 
Sixteen (37.2%) participants used hormonal contraception in their lifetime, four (9.3%) 
combined oral contraception and 12 (27.9%) DMPA (medroxyprogesterone acetate).  The 
remaining 62.8% have never used hormonal contraception and 2 (4.6%) have had bilateral 
tubal ligation. 
Previous cancer diagnosis 
Of the 43 participants included, 13 had previous colorectal surgery: 
 4 total colectomies for confirmed colon cancer 
 3 total colectomies for high grade dysplastic polyps 
 6 colectomies for low grade or multiple polyps (preventative surgery) 
 
Other medical history 
Five participants were receiving treatment for hypertension.  One of these five also had type2 
diabetes.   
Thirty-three participants had been tested for HIV previously.  Four (12%) tested positive and 
of these 2 participants were receiving anti-retroviral treatment. 
 
Twenty-one participants with proven hMLH1 mutation received full screening comprising of 
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Gynaecological examination 
Pelvic examination of the patients screened revealed no abnormalities. 
Papanicolau tests 
Twenty nine cervical smears were done.  Cytology testing revealed one ASCUS (atypical 
squamous cells of unknown significance).  Three smears had absent endocervical cells and 
had to be repeated.  Two smears showed Trichomonas and one Gardnerella infection.  
Ultrasound 
In total, thirty patients agreed to transvaginal ultrasound scans.  One adnexal mass was seen 
in a 69 year old female.  She was referred to the local district hospital for repeat pelvic 
ultrasound.  The endometrium thickness, size and morphology of the ovaries were measured 
where possible.  
Endometrial sampling 
Twenty-three endometrial biopsies were taken.  One (4%) patient was diagnosed with grade-
2 endometroid adenocarcinoma. No endometrial hyperplasia was diagnosed on biopsy.  Two 
biopsies were not possible due to cervical stenosis.  Ten biopsies were histologically 
suboptimal for diagnosis. 
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CHAPTER 4:  DISCUSSION AND RECOMMENDATIONS 
The literature states that women with Lynch syndrome have an increased risk for developing 
endometrial cancer and in to a lesser degree, ovarian cancer.  Screening recommendations 
have therefore been advised to diagnose early stage disease or premalignant lesions.  Less 
invasive treatment options would benefit the patient.   
Annual colonoscopy has proven to be of value to decrease colorectal cancer.  Although the 
international community recommends screening from the age of thirty, the efficacy of 
gynaecological screening is unclear in detecting cancer and also premalignant pathology. 
We screened a small group of women with a proven hMLH1 mutation or first degree family 
members of a known mutation carrier.  These women have never been screened for 
gynaecological cancer. In our study of 43 participants, 21 had a proven hMLH1 mutation and 
fulfilled our inclusion criteria to be screened.  The screening tests involved a transvaginal 
ultrasound and endometrial sampling.  Only one endometroid adenocarcinoma (1/21) has 
been detected.  One participant, with an adnexal mass was seen on ultrasound and this was 
consistent with a hydrosalpinx.  One cytology test was abnormal and showed ASCUS 
(atypical squamous cells of unknown significance).  
We assessed these patients demographic and gynaecological risk profile.  The majority of the 
participants (77%) had an increased BMI.  This is a well-known risk factor for developing 
endometrial cancer.  More than half of the participants (53%) were previous or current 
smokers.  Smoking cessation should be advised.  There were no other modifiable risk factors 
to gynaecological disease seen in this patient population.  
These patients have to travel long distances to their closest health care facilities.  Counselling 
aimed at informing the patients with Lynch syndrome of their increased risk of uterine and 
ovarian cancer should be offered at these annual screening opportunities.  Risk reducing 
strategies could possibly involve lifestyle modification 
The one participant diagnosed with grade 2 endometrioid endometrial cancer received 
surgery.  It is important to note that this patient was symptomatic and had postmenopausal 
bleeding for longer than 8 months.  She however, did not seek medical treatment despite 
adequate counselling by the genetic counsellor and research sister. 
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There has also been reluctance from the women undergoing annual colorectal screening to be 
seen by the gynaecologists.  The main reason the women gave for not wanting 
gynaecological screening was that they already had a colonoscopy and were reluctant for 
more invasive testing.   
Although endometrial sampling improves the sensitivity of the screening offered, it is 
invasive and not completely risk or pain free.  The quality of the specimen obtained is also 
limited and was reflected in the histology results.  Eleven (11/23) endometrial biopsies were 
assessed by the pathologist to be suboptimal.  These 11 correlated with an endometrial 
thickness of less than 6mm.  Endometrial sampling using a pipelle is a blind technique and 
ideally hysteroscopic directed biopsies should be performed. Transvaginal ultrasonography 
was well tolerated and might be a more acceptable approach for gynaecological screening in 
future. 
The low prevalence of gynaecological pathology in this group of patients could possibly be 
linked to their genetic mismatch repair system mutation.  There have been numerous studies 
to suggest females with the hMLH1 and hMSH2 gene mutation have a different phenotype to 
hMSH6 carriers.  hMSH6 carriers are much more prone to develop endometrial cancers while 
hMLH1 carriers seem to have a higher propensity toward proximal colorectal cancer [29].  
The number of subjects in our study is however, small. 
We found that the apparent prevalence of gynaecological disease in this study population was 
lower than expected (4.76%).   
We conclude however, that this high risk group with limited resources available to them 
warrants regular gynaecological screening. This should include a detailed history taking and 
clinical examination. Early symptom reporting should be advised to these women in order to 
detect possible early malignant changes. 
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APPENDICES: 
Appendix 1: Information leaflet 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
Title of the research project: 
The prevalence of gynaecological disease in patients with Lynch Syndrome 
REFERENCE NUMBER: 
PRINCIPAL INVESTIGATOR: Dr M Lerm 
CO-INVESTIGATORS:  Dr N Mbatani 
ADDRESS: University of Cape Town, WESTERN CAPE 
CONTACT NUMBER: 021- 404 4488 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the 
study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand what 
this research entails and how you could be involved.   
Your participation is entirely voluntary and you are free to decline to participate.  If you say 
no, this will not affect your care in any way whatsoever.  You can at any time withdraw from 
the study, even if you did agree to take part. 
This study has been approved by the Health Research Ethics Committee at the University of 
Cape Town and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice 
and the Medical Research Council (MRC) Ethical Guidelines for Research. 
What is this research study all about? 
We want to screen women with a known predisposition to colon cancer for any 
gynaecological abnormalities. We will do this research study when you come for your annual 
colonoscopy check-up at your clinic.  We are hoping to get more than 50 women to 
participate in the screening for gynaecological disease.   
Why have you been invited to participate? 
We are keen to talk to females with your condition as we hope to establish scientific 
information to improve knowledge of gynaecological cancers related to this genetic 
condition. We would also like to test for any other gynaecological conditions.  Our aim is to 
establish whether females with this genetic disorder are indeed at much higher risk than 
females without the disorder. 
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If you would like to participate in this study, the researchers will ask you a series of questions 
pertaining to your gynaecological health to ensure you are eligible to participate. 
Study Procedures 
Your involvement in the study will require one interview with the researcher during your 
yearly examination to look for colon cancer. We will ask some questions regarding your 
monthly period, contraception use, previous pregnancies and births.  We will also perform a 
pregnancy test to ensure you are not pregnant when we do further examinations. We will then 
do an ultrasound examination to look at the size and condition of your ovaries. 
When you are put to sleep (sedated) we will do a Pap smear to look for any early changes at 
the mouth of the womb that can result in cancer of the womb.   Then we will take a small 
biopsy of the lining of your womb. This might result in some cramping afterwards which 
should disappear within minutes. 
Potential Benefits 
You will be screened for gynaecological abnormalities.  In the case that we pick up any 
abnormalities the results will be discussed with your local doctor for further treatment. By 
participating in this study you will be making an important contribution to research that may 
benefit others in the future, as little is known about gynaecological problems in females with 
your condition. 
Potential Risks 
The ultrasound examination may cause you some discomfort but most women tolerate the 
procedure without any problems. As you will be asleep with the Pap smear and biopsy of the 
lining of your womb you will not feel any pain of discomfort. There might be some 
abdominal cramping and vaginal bleeding afterwards which should settle within minutes. 
Compensation 
No compensation will be offered for participation, but there will also be no costs involved for 
your gynaecological consultation. 
Confidentiality 
Your participation is regarded as strictly confidential and not shared with other parties. You 
will be given a number so that your name will not be connected to your questionnaire. Any 
data reported from this study would not identify individuals.  All information will be kept in 
locked file cabinets accessible only to the principal investigator and the research team. Any 
publications/lectures/reports resulting from this study will not identify you by name or any 
other means. 
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The right to ask questions/withdraw from this study 
Your participation in this study is entirely voluntary. You have the right to withdraw at any 
time.  If you decide not to partake / to withdraw from this study, this will not jeopardize you 
or the treatment you may require in any way.  If you have any queries, you can contact Dr 
Marlize Lerm at 021 404 4488.  
You can contact the Health Research Ethics Committee at 021 406 6626 for any concerns or 
complaints that have not been adequately addressed by your study doctor. You will receive a 
copy of this information and consent form for your own records. 
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Appendix  2: Consent form 
Declaration by participant 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled (The prevalence of gynaecological disease in patients with Lynch 
syndrome) 
 I declare that: 
 I have read or had read to me this information and consent form and it is written in a
language with which I am fluent and comfortable.
 I have had a chance to ask questions and all my questions have been adequately
answered.
 I understand that taking part in this study is voluntary and I have not been pressurized
to take part.
 I may choose to leave the study at any time and will not be penalized or prejudiced in
any way.
 I may be asked to leave the study before it has finished, if the study doctor or
researcher feels it is in my best interests, or if I do not follow the study plan, as agreed
to.
Signed at (place) ......................…........……….. on (date) ………………….……… 2015. 
Signature of participant Signature of witness 
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Declaration by investigator 
I (name) ……………………………………………..……… declare that: 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them.
 I am satisfied that he/she adequately understands all aspects of the research, as
discussed above
 I did/did not use a interpreter.  (If a interpreter is used then the interpreter must sign
the declaration below.
Signed at (place) ......................…........…………….. on (date) …………....……….. 2015. 
Signature of investigator Signature of witness 
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Declaration by interpreter 
I (name) ……………………………………………..……… declare that: 
 I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer them.
 I conveyed a factually correct version of what was related to me.
 I am satisfied that the participant fully understands the content of this informed
consent document and has had all his/her question satisfactorily answered.
Signed at (place) ......................…........…………….. on (date) …………....……….. 2015. 
Signature of interpreter Signature of witness 
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Appendix 3: Research approval letter from HREC 
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Appendix 4: Data sheet demographic and clinical history 
Study nr: 
Age: 
Address/ Local clinic: 
Level of education: 
Employment status: 
 G__ P __ M __ E__ T__ 
Menarche: 
Last menstrual period:  
Menstrual irregularities:  





Depot COC IUCD Tubal ligation 
Last used / comment:________________________________________ 
Pregnancy status/ NA/ Prognostix POS / NEG 
Menopausal : Y / N                  If Y, Duration (in years): 
 Menopausal symptoms:______________________________________ 
Any family history of a gynaecological cancer? _________________________________ 
Is affected member gene mutation pos/unknown 
Smoking history: Y / N / Previous 
HIV status: Pos / neg / unknown 
Previous Pap Smear result if any: 
Less than 3 years ago 3-10 years >10 years
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Appendix 5: Data sheet examination and ultrasound 
EXAMININATION 
Body Mass Index (BMI): 





PV and speculum: 
Cervix normal Y / N 
Endometrial biopsy done Y / N 
Comment:___________________________________________________ 
Transabdominal and/or transvaginal ultrasound: 
Uterus 




Left:_______________    
Right:______________ 
Ascites? Y / N 
Morphology: 
Normal / Cystic / 
Septated / Solid 
COMMENT: 
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Appendix 6:  ICG-HNPPC Amsterdam criteria I and II 
